MD Anderson Cancer Center

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Medical Devices, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCPCS, Interest, Second Half, Patient, APC, Sale, Society, University, Bank statement, Investment, Therapy, Marketing, DCR, Webcast, Hepatocellular carcinoma, CMS, Abdominal ultrasonography, Vein, Disease, Opinion, Immunotherapy, Safety, Manuscript, Cholangiocarcinoma, Pancreas, PFS, FDA, Liver disease, HCC, OS, Uveal melanoma, MDSC, Growth, TACE, Commander, U.S. Pacific Fleet, Drug, MD Anderson Cancer Center, Data, Medicare, Liver, Pharmaceutical industry

TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • This new code, HCPCS 9797, has been assigned to the Ambulatory Payment Classification (APC) 5194 – Level 4 Endovascular Procedures.
  • The Company is working diligently to evaluate the materiality of the errors to determine whether any corrections for the third quarter financial results are required and to complete the Company’s year-end 2023 financial statements.
  • Operating losses were $14.1 million and $54.2 million, respectively, for the fourth quarter and full year ended December 31, 2023.

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Other Health, Health, Radiology, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Interventional radiology, Thrombosis, TLR9, MDSC, Immunotherapy, Drug, Progression-free survival, Patient, Cancer, Bleeding, Society, University, Neoplasm, MD Anderson Cancer Center, Pancreas, FACS, Liver

Technology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting.

Key Points: 
  • Technology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting.
  • In PERIO-03, nelitolimod is delivered via the PEDD method with the TriSalus Infusion System using a retrograde venous approach, leveraging established interventional radiology access techniques.
  • There were no immediate complications from the procedure, and there was no evidence of hemorrhage or thrombosis.
  • Local tumor progression-free survival rates across organs at one month, six months, and one year were 94%, 80%, and 70%, respectively.

Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Citigroup, Rabin Medical Center, Biomedicine, Biomedical engineering, Partnership, Tiger Management, Business, Duke University, Duke University Hospital, NDA, Acquisition, Credit Suisse, University, MD Anderson Cancer Center, Therapy, Bangladesh Technical Education Board, STAT3, Pharmaceutical industry

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.

Key Points: 
  • Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.
  • Formerly, Mr. Shah was a healthcare investment banker for global investment banks Citigroup and Credit Suisse.
  • Newly appointed board member Dr. Wirk has more than 20 years of investment experience in public and private life science companies.
  • “The appointment of Sujal as Chairman and the addition of Shaheen to Tvardi’s Board of Directors are instrumental to the success of Tvardi,” said Imran Alibhai, Ph.D., CEO of Tvardi.

Lumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual Meeting

Retrieved on: 
Monday, March 25, 2024
Health, Surgery, Oncology, Medical Devices, Breast cancer, Feasibility, Detection, DVS, Massachusetts General Hospital, Light, Inc., Patient, Neoplasm, Stanford University Medical Center, NDA, University, Doctor of Philosophy, Society, Surgeon, Patient satisfaction, Surgical oncology, SSO, Hospital, PMA, Multimedia, MD Anderson Cancer Center, FDA, Associate professor, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240325761901/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240325761901/en/
    Barbara Smith, M.D, PhD., presented results from the INSITE study during the Breast Cancer Hub Zone talk during the SSO Annual Meeting 2024.
  • “It’s so energizing to see such a diversity of surgeons across different specialties come together to advance the collective field of surgical oncology,” said Jorge Ferrer, M.D., PhD, Chief Scientific Officer, Lumicell.
  • Most recently, the FDA’s Medical Imaging Drugs Advisory Committee (MIDAC) voted in support of the benefit-risk profile of LUMISIGHT™ (pegulicianine) during its March 5, 2024 meeting .
  • The FDA is expected to make a decision on Lumicell’s NDA and PMA in the near future.

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Retrieved on: 
Tuesday, March 19, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, AP, Mutation, BP, Disease, New Drug Application, Patient, ALL, Shanda, CML, MD, University, MD Anderson Cancer Center, Priority review, MRD, CP, TKI, Glomus tumor, Food, Pharmaceutical industry

Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
  • This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
  • ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.

Enstor Gas Adds Industry Veteran Jennifer Johnson as General Counsel

Retrieved on: 
Monday, March 18, 2024
Energy, Legal, Professional Services, Oil, Gas, Permian, Slate, Juris, MD Anderson Cancer Center, University, Acquisition, Noble Energy, University of Texas System, Nursing, Multimedia, Willkie Farr & Gallagher, The Honourable

Enstor Gas (“Enstor”), the largest privately owned gas storage company in the United States, is pleased to announce that Jennifer Johnson has joined the company as general counsel.

Key Points: 
  • Enstor Gas (“Enstor”), the largest privately owned gas storage company in the United States, is pleased to announce that Jennifer Johnson has joined the company as general counsel.
  • View the full release here: https://www.businesswire.com/news/home/20240318446853/en/
    Enstor Gas general counsel Jennifer Johnson (Photo: Business Wire)
    Before joining Enstor, Jennifer served as general counsel for Salt Creek Midstream where she managed legal, sustainability, and human resources aspects of the business, including governance and finance matters, sustainability reporting, the acquisition and divestiture of energy assets, commercial contracts, litigation and disputes, and regulatory and compliance related matters.
  • Prior to joining Salt Creek, Ms. Johnson served as vice president, general counsel and corporate secretary of Rosehill Resources, Inc., a publicly traded upstream company with assets in the Permian Basin.
  • “Enstor is thrilled to welcome Jennifer on board as general counsel and a key contributing member of our management team,” said Enstor CEO Paul Bieniawski.

Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors

Retrieved on: 
Monday, March 11, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Pharmacology, PARP1, Senior, HRD, Medicine, University, CNS, Patient, MD Anderson Cancer Center, PARP, Therapy, Cancer, Safety, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.
  • SNV1521 is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.
  • In preclinical models, selective PARP1 targeting has been shown to improve both the efficacy and safety of the class.
  • “Dosing of the first patient in the SNV1521 Phase I trial is a key milestone as Synnovation transitions from a preclinical to clinical stage biotech company.

Bipartisan Legislation Makes Patient Safety a National Priority

Retrieved on: 
Monday, March 11, 2024
Nursing, Public Policy, Government, Healthcare Reform, Other Health, White House, Federal Government, Managed Care, Health, General Health, Other Policy Issues, Wolk, Culture, Algorithm, Fungal infection, Learning, Partnership, MedStar Health, COVID-19, Patient, NPSB, Research, News, Aviation, Long-term care, AI, Human services, University, Death, Doctor of Philosophy, MD, MD Anderson Cancer Center, Data collection, Chill, Safety, Patient safety, Pathology, Brain damage, Family, Approximation error, Legislation

This landmark bipartisan legislation, announced during Patient Safety Awareness Week, is a critical step to improve safety for patients and healthcare providers by adopting patient safety solutions.

Key Points: 
  • This landmark bipartisan legislation, announced during Patient Safety Awareness Week, is a critical step to improve safety for patients and healthcare providers by adopting patient safety solutions.
  • The National Patient Safety Board Act would create a National Patient Safety Board (NPSB), a data-driven, nonpunitive, collaborative, independent research and development team housed within the Department of Health and Human Services to address safety in health care.
  • The establishment of a National Patient Safety Board would enable a collaborative, evidence-based and scalable solution to optimize patient safety across our country’s healthcare system,” said Peter WT Pisters, MD, president of The University of Texas MD Anderson Cancer Center.
  • “Patient safety is our number one priority for every decision we make as a health system.

Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York.

Retrieved on: 
Monday, April 1, 2024
Research, Pacritinib, JAK2, Bone marrow, Blood transfusion, CXCR4, Inflammation, Patient, University, Ruxolitinib, Clinical trial, CXCL12, Fedratinib, Safety, Pancreatic serous cystadenoma, University of California, Davis, MD Anderson Cancer Center, Albert Einstein Israelite Hospital, Pharmaceutical industry

Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.

Key Points: 
  • Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.
  • This research will be conducted under the guidance of Ronald Hoffman, MD, Albert A. and Vera G. List Professor of Medicine and Director of the Myeloproliferative Disorders Research Program at The Tisch Cancer Institute- Mount Sinai.
  • CK0804 is a novel allogeneic, CXCR4 enriched, Treg cell therapy product that utilizes Cellenkos' proprietary CRANE® technology to generate disease specific products.
  • Dr. Ronald Hoffman serves as a paid consultant for Cellenkos.

Women are Reshaping the AI Talent Landscape New Research Shows Exponential Global Growth

Retrieved on: 
Wednesday, March 20, 2024
Research, Microsoft, Boston Consulting Group, Health, Organization, University, Apple, Woman, Amazon, Science, Intelligence, Roche, Meta, Female, ETS, Big, Data, MD Anderson Cancer Center, Engineering, Medical device

Zeki's AI dataset is the only of its kind in the world--- including more than 133,000 individuals and over 2 million unique data points. In this Women in AI 2024 report, Zeki has ranked and scored 33,000+ women from 109 countries educated or working at over 4,300 universities or employed by over 42,000 companies or organisations globally.

Key Points: 
  • In this Women in AI 2024 report , Zeki has ranked and scored 33,000+ women from 109 countries educated or working at over 4,300 universities or employed by over 42,000 companies or organisations globally.
  • These precise, data-led insights focus on where and how to find, attract, and retain top women in AI.
  • University Attraction- US universities are training increasing numbers of top women in AI, yet women only represent roughly 22% of scientists and engineers in major US university AI labs.
  • For expanded insights, see Zeki's flagship report, the State of AI Talent 2024 , for actionable intelligence on the countries, companies, universities, and sectors winning and losing in the race for top AI talent.